A Combined GLP-1/PPARa/CB1-Based Therapy to Restore theCentral and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet DOI Open Access
Marialuisa de Ceglia, Nabila Rasheed, Rubén Tovar

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(6), С. 2420 - 2420

Опубликована: Март 7, 2025

Obesity remains a major epidemic in developed countries, with limited range of effective pharmacological treatments. The modulation PPARα, CB1, or GLP-1 receptor activity has demonstrated beneficial effects, including anti-obesity actions. In this study, we evaluated novel amide derivative oleic acid and tyrosol (Oleyl hydroxytyrosol ether, OLHHA), PPARα agonist, CB1 antagonist, combination the agonist liraglutide (LIG), as an multitarget therapy to improve both peripheral central alterations animal model diet-induced obesity. rats, exposure high-fat high-fructose diet (HFHFD) induced weight gain increased plasma triglycerides, LDL, hepatic parameters. brain, HFHFD provoked disruptions expression proteins regulating food intake, endocannabinoid system, insulin pathway, inflammation resulted altered tau phosphorylation, thus indicating neurodegenerative changes. Based on our results, administration LIG OLHHA alone was insufficient completely reverse noticed at levels. On other hand, combined treatment compounds (OLHHA+LIG) most promoting body loss ameliorating by HFHFDs rats. This therapeutic approach could represent promising strategy for treating obesity associated comorbidities.

Язык: Английский

A Combined GLP-1/PPARa/CB1-Based Therapy to Restore theCentral and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet DOI Open Access
Marialuisa de Ceglia, Nabila Rasheed, Rubén Tovar

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(6), С. 2420 - 2420

Опубликована: Март 7, 2025

Obesity remains a major epidemic in developed countries, with limited range of effective pharmacological treatments. The modulation PPARα, CB1, or GLP-1 receptor activity has demonstrated beneficial effects, including anti-obesity actions. In this study, we evaluated novel amide derivative oleic acid and tyrosol (Oleyl hydroxytyrosol ether, OLHHA), PPARα agonist, CB1 antagonist, combination the agonist liraglutide (LIG), as an multitarget therapy to improve both peripheral central alterations animal model diet-induced obesity. rats, exposure high-fat high-fructose diet (HFHFD) induced weight gain increased plasma triglycerides, LDL, hepatic parameters. brain, HFHFD provoked disruptions expression proteins regulating food intake, endocannabinoid system, insulin pathway, inflammation resulted altered tau phosphorylation, thus indicating neurodegenerative changes. Based on our results, administration LIG OLHHA alone was insufficient completely reverse noticed at levels. On other hand, combined treatment compounds (OLHHA+LIG) most promoting body loss ameliorating by HFHFDs rats. This therapeutic approach could represent promising strategy for treating obesity associated comorbidities.

Язык: Английский

Процитировано

0